Open Veils · Answer
Fibrocystic breasts
Mainstream medicine calls it benign and cyclical, but suppressed nutritional and endocrine research points to fibrocystic changes as a downstream signal of iodine deficiency, estrogen dominance, and methylxanthine toxicity — addressable at the root. The 'not a disease' framing conveniently sidesteps why the condition has become epidemic. Practitioners in the Weston A. Price and functional medicine traditions treat it as a metabolic canary.
Evidence
- Dr. David Brownstein, a prominent iodine researcher, has documented that fibrocystic breast tissue responds dramatically to iodine repletion — specifically molecular iodine (I₂) rather than iodide.
- The estrogen-dominance angle is amplified by John R. Lee, whose decades of work on progesterone deficiency identified unopposed estrogen as the driver of both fibrocystic changes and eventual malignancy risk.
- Methylxanthines — caffeine, theophylline, theobromine — were specifically linked to fibrocystic disease by John Minton's research in the late 1970s.
- Jack Kruse frames fibrocystic pathology within mitochondrial and circadian biology: artificial light exposure alters melatonin rhythms, which disrupts the prolactin-estrogen axis and promotes cystic breast remodeling.
- Gary Taubes and Nina Teicholz's work on insulin and metabolic syndrome provides a further layer: hyperinsulinemia upregulates IGF-1 and aromatase activity, raising local estrogen production in breast adipose tissue, creating the hormonal substrate that all the above researchers identify as the proximate cause.